Entropy Technologies LP Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Entropy Technologies LP lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,400 shares of the medical equipment provider's stock after selling 4,185 shares during the quarter. Entropy Technologies LP's holdings in Hologic were worth $606,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Benson Investment Management Company Inc. bought a new stake in shares of Hologic during the 4th quarter worth about $4,832,000. Clean Yield Group boosted its stake in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after acquiring an additional 7,266 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock worth $2,344,000 after acquiring an additional 800 shares in the last quarter. Versor Investments LP bought a new stake in shares of Hologic during the 3rd quarter worth about $1,677,000. Finally, JPMorgan Chase & Co. boosted its stake in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after purchasing an additional 238,222 shares during the period. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. William Blair restated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. UBS Group raised their price objective on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price objective for the company. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has an average rating of "Moderate Buy" and an average price target of $85.77.

Hologic Trading Down 0.6 %

Shares of NASDAQ:HOLX traded down $0.38 during midday trading on Friday, hitting $63.24. The company had a trading volume of 2,320,041 shares, compared to its average volume of 2,558,621. Hologic, Inc. has a 12 month low of $62.94 and a 12 month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.27 billion, a price-to-earnings ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97. The firm has a fifty day simple moving average of $71.04 and a 200 day simple moving average of $77.22.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.88% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.